MENARINI is a fully integrated privately owned pharma company with a long and successful heritage in strategic partnering across the globe. We have a profound know-how stemming from our strong R&D capabilities in key therapeutic areas, coupled with our excellence in commercial execution and our powerful direct presence on a global basis.
Colorectal Cancers
Colorectal cancer remains a leading cause of cancer-related death worldwide despite the advances attributed to cancer screening programs, improved surgical techniques and effective chemotherapy. The introduction of targeted therapies and immunotherapy together with better biomarker risk stratification methods have led to a qualified improvement in survival and many challenges remain. At Menarini we are assessing how best to improve drug development strategies from the metastatic to the adjuvant setting using rationale combinations of targeted therapies in different subtypes of colorectal cancer.
